| Nome |
# |
|
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years, file e1dcb335-285c-7715-e053-1705fe0a6cc9
|
273
|
|
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma, file 408481ab-e2a7-45e5-9af7-2c7cf09940f9
|
256
|
|
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study, file e1dcb335-6035-7715-e053-1705fe0a6cc9
|
222
|
|
Expression of CD52 in peripheral T-cell lymphoma., file e1dcb331-8049-7715-e053-1705fe0a6cc9
|
135
|
|
Consensus conference on the management of tumor lysis syndrome., file e1dcb331-ceac-7715-e053-1705fe0a6cc9
|
122
|
|
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials., file e1dcb331-957a-7715-e053-1705fe0a6cc9
|
121
|
|
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia, file e1dcb334-51e6-7715-e053-1705fe0a6cc9
|
114
|
|
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients, file e1dcb333-91a9-7715-e053-1705fe0a6cc9
|
105
|
|
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue, file e1dcb334-1ed2-7715-e053-1705fe0a6cc9
|
102
|
|
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report, file e1dcb332-f8d2-7715-e053-1705fe0a6cc9
|
100
|
|
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up., file e1dcb331-aa5e-7715-e053-1705fe0a6cc9
|
94
|
|
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience, file e1dcb333-6fd6-7715-e053-1705fe0a6cc9
|
89
|
|
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS, file e1dcb334-4133-7715-e053-1705fe0a6cc9
|
87
|
|
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results, file e1dcb334-f6ec-7715-e053-1705fe0a6cc9
|
80
|
|
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients, file e1dcb334-89b5-7715-e053-1705fe0a6cc9
|
78
|
|
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma, file e1dcb337-8f97-7715-e053-1705fe0a6cc9
|
77
|
|
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers, file e1dcb335-73d1-7715-e053-1705fe0a6cc9
|
69
|
|
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series, file e1dcb335-45ef-7715-e053-1705fe0a6cc9
|
68
|
|
Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy, file a0af0c34-3f20-4931-a58c-79068ec07be4
|
67
|
|
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma, file e1dcb334-4fce-7715-e053-1705fe0a6cc9
|
67
|
|
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia, file e1dcb335-375c-7715-e053-1705fe0a6cc9
|
66
|
|
Microplastics shape the ecology of the human gastrointestinal intestinal tract, file e1dcb338-ba30-7715-e053-1705fe0a6cc9
|
65
|
|
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience., file 4731cf19-a346-4ee2-b8ee-589d236f7310
|
64
|
|
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi, file e1dcb334-323c-7715-e053-1705fe0a6cc9
|
63
|
|
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers., file e1dcb335-019b-7715-e053-1705fe0a6cc9
|
63
|
|
Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression., file e1dcb334-facc-7715-e053-1705fe0a6cc9
|
57
|
|
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma, file e1dcb335-72bb-7715-e053-1705fe0a6cc9
|
57
|
|
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients, file e1dcb335-f83a-7715-e053-1705fe0a6cc9
|
57
|
|
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma, file 59d91470-0a52-4cb0-abf6-8ef195c04d2d
|
56
|
|
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study, file e1dcb33a-234c-7715-e053-1705fe0a6cc9
|
55
|
|
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma, file e1dcb335-794c-7715-e053-1705fe0a6cc9
|
54
|
|
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study, file e1dcb335-4535-7715-e053-1705fe0a6cc9
|
50
|
|
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab, file e1dcb335-28e2-7715-e053-1705fe0a6cc9
|
49
|
|
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials, file e1dcb337-4b0f-7715-e053-1705fe0a6cc9
|
46
|
|
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas, file e1dcb334-4118-7715-e053-1705fe0a6cc9
|
44
|
|
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience, file e1dcb33a-3227-7715-e053-1705fe0a6cc9
|
41
|
|
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma, file e1dcb336-6ee1-7715-e053-1705fe0a6cc9
|
40
|
|
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective, file e1dcb337-4e35-7715-e053-1705fe0a6cc9
|
39
|
|
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial, file e1dcb339-0155-7715-e053-1705fe0a6cc9
|
36
|
|
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation, file 78eff9c8-ff6b-4976-bc78-1b8f4cb55958
|
32
|
|
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy., file 4ad05aba-df6a-42b7-88b8-5bd319fd51c5
|
30
|
|
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation., file e1dcb331-436a-7715-e053-1705fe0a6cc9
|
28
|
|
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, file 699d4dc9-aea0-4e8d-8fbf-b265a99ca925
|
26
|
|
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma, file 7e4571f7-255f-4b5c-8cf1-48a747ea67ed
|
25
|
|
Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region, file 46a64553-b6ef-4109-a010-d8988b105e84
|
24
|
|
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome, file e1dcb331-8047-7715-e053-1705fe0a6cc9
|
24
|
|
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy, file 71f06c47-d85a-4656-8b91-af7c55679358
|
23
|
|
Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma, file 0b9ece79-7c8c-4a3b-903b-b2f217069af3
|
22
|
|
Successful Pregnancies, Births, and Children Development Following Oocyte Cryostorage in Female Cancer Patients During 25 Years of Fertility Preservation, file 12585aa4-f384-4f76-a99c-959ea2467330
|
20
|
|
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial, file f65a345d-ae23-4b7c-a9e5-0cdf28a41055
|
20
|
|
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients, file 2ab358ad-aa00-4201-bcb7-7b6b63e97a25
|
19
|
|
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity, file dd104b0e-942d-40b0-8e2e-3957bbf4cf61
|
19
|
|
Controversies in the Treatment of Peripheral T-cell Lymphoma, file 350792ee-ed2d-4f6b-ac2b-d2485a9500ad
|
17
|
|
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study, file f6bd62e5-9292-409c-a8cb-8e425cfe6976
|
17
|
|
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature, file 37b032f2-c87f-45ae-92d5-db0bd945b581
|
16
|
|
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia, file ced17cde-11fa-421f-89df-0fcc9a20ac12
|
14
|
|
A 3-decade multicenter European experience with cladribine as upfront treatment in 384 hairy cell leukemia patients, file 596a8fe3-645f-4f8e-9cb1-b50acf30ab64
|
13
|
|
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors, file e1dcb33a-0f7b-7715-e053-1705fe0a6cc9
|
13
|
|
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study, file e96c1617-928a-4e66-ba46-a166772e9dd6
|
12
|
|
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial, file 83c25d09-0e4f-4c75-90da-deeea6aa71f4
|
11
|
|
18 F-FDG PET in malignant lymphoma: significance of positive findings, file e1dcb32f-2352-7715-e053-1705fe0a6cc9
|
11
|
|
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma, file 25ee5eea-b0b2-4f0b-9ec2-0e66acfef706
|
10
|
|
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia, file 9dcb8094-999a-4e2e-8da2-83f6eb289375
|
10
|
|
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy, file ec95d801-979e-4e5d-a17e-20eec08acb04
|
10
|
|
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder, file 24314afe-0afc-4e4a-8373-e799a8b1cc83
|
9
|
|
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma, file 86e10278-8b50-492e-95d2-cac59640ed90
|
9
|
|
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience, file 9b1013e6-644a-4333-b38f-d5ab42aec7a9
|
9
|
|
The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis, file e1dcb331-2cb5-7715-e053-1705fe0a6cc9
|
9
|
|
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report, file 3fe60275-29c6-4d86-b461-ad84fc79cc20
|
8
|
|
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data, file 58c00398-2eac-4dc8-832b-3171fd66ebb3
|
8
|
|
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma, file 863f5bb8-a0f0-4d73-a21d-d8d7ad51e029
|
8
|
|
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab, file 999899dc-79ed-47a1-bf80-0e2747450cbf
|
8
|
|
Pi3kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients, file 9d82e893-b45d-46cc-82fe-f1d787cd63a9
|
8
|
|
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma, file bae53c4b-6b41-43f1-80b7-448a1a9afd5a
|
8
|
|
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma, file e1dcb336-d062-7715-e053-1705fe0a6cc9
|
8
|
|
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial, file 063c369c-a0b2-4322-a75c-760ef2999fbb
|
7
|
|
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma, file 6ac2510c-7bf9-4396-a634-6c6a014d0db0
|
7
|
|
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity, file ff50c11e-3afa-43cc-bdf6-aeda95eecdde
|
7
|
|
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis, file 240cc55d-af78-4dd4-9446-6eef15c5942d
|
6
|
|
Integrated safety analysis of umbralisib, a dual PI3Kd/CK1« inhibitor, in relapsed/refractory lymphoid malignancies, file 91b763d9-8be5-472f-8ee7-1fcff3d514ce
|
6
|
|
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study, file a97b4c39-6b68-4e99-bf2f-5efb79db51e2
|
6
|
|
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma, file b81f212a-7396-411e-8ec0-9031e5d99d5b
|
6
|
|
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma, file b949b36c-73c3-4229-a1f3-9bea0b1a9b3e
|
6
|
|
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study, file e1dcb335-4536-7715-e053-1705fe0a6cc9
|
6
|
|
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study, file e1dcb335-4537-7715-e053-1705fe0a6cc9
|
6
|
|
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, file e1dcb338-678b-7715-e053-1705fe0a6cc9
|
6
|
|
Is good clinical practice becoming poor clinical care?, file 248a0f9b-3889-468f-90ea-70a4f7f9060f
|
5
|
|
Methodological framework for radiomics applications in Hodgkin’s lymphoma, file 9967e02e-394a-4cf5-aa6a-01d8a6de9d1b
|
5
|
|
Development of a distributed international patient data registry for hairy cell leukemia, file b408ab0d-729e-400f-84a8-0b2c2c404176
|
5
|
|
Persistent agmination of lymphomatoid papulosis: an ongoing debate., file e1dcb32c-1a57-7715-e053-1705fe0a6cc9
|
5
|
|
Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma, file e1dcb331-6290-7715-e053-1705fe0a6cc9
|
5
|
|
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments, file e1dcb334-35be-7715-e053-1705fe0a6cc9
|
5
|
|
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study, file ffae0e57-199a-4f7c-87e4-cb8e25db5b0d
|
5
|
|
New Treatment Options in Advanced Stage Follicular Lymphoma, file 013b2b45-94db-4ccd-b416-92cfc8e10cc1
|
4
|
|
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma, file 2074ff33-2d41-4650-b5c7-f9d2d29c13ed
|
4
|
|
Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study, file 36a0734b-0320-4412-93b8-3c2a36633321
|
4
|
|
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy, file 596050f0-2ae0-4cbd-ad63-e2a65fcb6320
|
4
|
|
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study, file 75e07776-90ee-44c0-a2e5-551055d20870
|
4
|
|
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines, file 7c8dc16e-0b49-48a7-8f85-c569098ca33e
|
4
|
|
Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study, file 7e4efe2d-c14e-4c5d-80f3-12f364eadfc9
|
4
|
| Totale |
4.018 |